Andere talen CombiGene AB

Aandelen

Vertraagde tijd Nasdaq Stockholm Andere beurzen 10:04:17 27-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,02 ^SEK	0,00%		-2,58%	+12,27%

24/06	CombiGene sluit een licentieovereenkomst met Spark voor het epilepsieproject CG01	CI
27/05	CombiGene benoemt nieuwe Chief Scientific Officer	MT

BioStock: CombiGene positive to new license agreement for CG01	26/06
Västra Hamnen publishes initial analysis of CombiGene	25/06
CombiGene enters into a license agreement with Spark for the epilepsy project CG01	24/06
CombiGene Enters into A License Agreement with Spark for the Epilepsy Project CG01	24/06
CombiGene: Preclinical experts in gene therapy	20/06
CombiGene selects Västra Hamnen Corporate Finance as new Certified Adviser	14/06
BioStock: She is CombiGene's new CSO	31/05
CombiGene Appoints New Chief Scientific Officer	27/05
CombiGene appoints new Chief Scientific Officer	27/05
Combigene AB Appoints Annika Ericsson as New Chief Scientific Officer	27/05
Bulletin from the annual general meeting of CombiGene AB (publ)	23/05
CombiGene AB Approves Election of Marcus Isaksson as Board Member	23/05
Interim report January – March 2024 for CombiGene AB (publ)	17/05
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2024	17/05
BioStock: CombiGene's pain programme takes important steps forward	03/05
CombiGene AB (publ) publishes annual report for 2023	26/04
Notice of Annual General Meeting in CombiGene AB (publ)	18/04
BioStock: CombiGene's CEO comments on the patent approvals in Australia and India	20/03
CombiGene’s epilepsy project CG01 has been granted patent in two new countries	13/03
CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries	13/03

Geen resultaten voor deze zoekopdracht